Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. “Dual agonist” describes receptor pharmacology; it is not a certificate of clinical status or proof that two materials with the same short name are equivalent.
What the record shows
- Phase 2 and phase 3 results must be attributed to the studied formulation and population.
- The 2026 phase 3 paper still describes survodutide as investigational.
- Sequence, counterion, purity, content and impurity controls remain lot-specific questions.
The identity and evidence boundary
The phase 2 program established a dose-ranging signal, while SYNCHRONIZE-1 supplied the first published phase 3 obesity result. Those records answer clinical-development questions. They do not answer whether a catalog lot has the same sequence, formulation, exposure profile or manufacturing controls.
What belongs in the material record
For research procurement, record the exact sequence and molecular form, peptide content, chromatographic method, mass confirmation, water and counterion information, and any aggregation or impurity requirements. Avoid describing a research material as the clinical intervention without documentary linkage.
Editorial rule
Use the exact intervention name, model, population and endpoint from the cited record. Do not convert an association, mechanism, animal result, approved finished-drug record or analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Survodutide Once Weekly for the Treatment of Adults with Obesityle Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
- Survodutide phase 2 obesity trialDose-ranging clinical context; PMID 38330987.
- SYNCHRONIZE-1 trial registryClinicalTrials.gov NCT06066515.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
